Literature DB >> 12006921

The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women.

Lucia A Hindorff1, Stephen M Schwartz, David S Siscovick, Bruce M Psaty, W T Longstreth, Alexander P Reiner.   

Abstract

BACKGROUND: The plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G insertion/deletion polymorphism has been associated with increased risk of myocardial infarction (MI) and decreased risk of cerebrovascular events. Whether these results apply to young women is not known.
METHODS: We genotyped 78 MI cases, 106 stroke cases and 385 age-matched controls from a population-based case-control study of MI and stroke in women < 45 years old.
RESULTS: The risk of MI was significantly decreased in carriers of the 4G allele compared with 5G/5G homozygotes, and the association persisted upon adjustment for other risk factors (age- and race-adjusted OR 0.50, 95% CI 0.29-0.85). Carrying the 4G allele was not associated with stroke, either overall or according to subtype. The association of this polymorphism with MI or stroke did not vary significantly by presence or absence of established cardiovascular risk factors, assessed on either an additive or multiplicative scale.
CONCLUSIONS: These data suggest a decreased risk of MI among young women carrying the 4G allele of the PAI-1 4G/5G polymorphism. Although this result contrasts with those of previous studies of older adults and young men, it may highlight the influence of genetic factors on the development of MI within the context of particular hormonal or environmental influences.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006921     DOI: 10.1177/174182670200900209

Source DB:  PubMed          Journal:  J Cardiovasc Risk        ISSN: 1350-6277


  15 in total

1.  Thrombophilias and stroke: diagnosis, treatment, and prognosis.

Authors:  Madeline C Fields; Steven R Levine
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

2.  Pai-1 gene variants and COC use are associated with stroke risk: a case-control study in the Han Chinese women.

Authors:  Xiaoping Huang; Ying Li; Zhizheng Huang; Chun Wang; Zhenlin Xu
Journal:  J Mol Neurosci       Date:  2014-09-18       Impact factor: 3.444

3.  Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke.

Authors:  Adriano de Paula Sabino; Daniel Dias Ribeiro; Caroline Pereira Domingueti; Mariana Silva Dos Santos; Telma Gadelha; Luci Maria Santana Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  Mol Biol Rep       Date:  2011-03-04       Impact factor: 2.316

4.  Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.

Authors:  G H Tofler; J Massaro; C J O'Donnell; P W F Wilson; R S Vasan; P A Sutherland; J B Meigs; D Levy; R B D'Agostino
Journal:  Thromb Res       Date:  2016-02-03       Impact factor: 3.944

5.  Association between the rs6950982 polymorphism near the SERPINE1 gene and blood pressure and lipid parameters in a high-cardiovascular-risk population: interaction with Mediterranean diet.

Authors:  Mercedes Sotos-Prieto; Marisa Guillén; Olga Portolés; José V Sorlí; José I González; Eva M Asensio; Dolores Corella
Journal:  Genes Nutr       Date:  2012-12-09       Impact factor: 5.523

Review 6.  Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.

Authors:  Xin Hu; Xin Zan; Zhiyi Xie; Yunke Li; Sen Lin; Hao Li; Chao You
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

7.  Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.

Authors:  Loukianos S Rallidis; Argyri Gialeraki; Efrosyni Merkouri; George Liakos; Nikolaos Dagres; Dimitrios Sionis; Anthi Travlou; John Lekakis; Dimitrios T Kremastinos
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

8.  Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.

Authors:  Orhan Onalan; Gunay Balta; Ali Oto; Giray Kabakci; Lale Tokgozoglu; Kudret Aytemir; Cigdem Altay; Aytemiz Gurgey; Nasih Nazli
Journal:  J Thromb Thrombolysis       Date:  2007-08-25       Impact factor: 2.300

9.  Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.

Authors:  C Nafría; I Fernández-Cadenas; M Mendioroz; S Domingues-Montanari; M Hernández-Guillamón; J Fernández-Morales; A Del Río-Espínola; D Giralt; L Deu; P Delgado; A Rosell; J Montaner
Journal:  Stroke Res Treat       Date:  2011-06-09

10.  Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia.

Authors:  Emin Alioglu; Nurullah Tuzun; Fahri Sahin; Buket Kosova; Serkan Saygi; Istemihan Tengiz; Ugur Turk; Nazan Ozsan; Ertugrul Ercan
Journal:  Thromb J       Date:  2009-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.